The Rapidly Evolving Landscape of Biomarker Testing in Non­–Small Cell Lung Cancer

Although lung cancer remains the leading cause of cancer-related death in the United States, the past decade has seen continuous declines in mortality, with age-adjusted death rates falling on average 3.3% each year over 2008–2017. Further progress in these encouraging trends will in part be tied to continued advances in identifying oncogenic genomic alterations and the development of targeted therapies for non-small cell lung cancer (NSCLC), particularly nonsquamous NSCLC (ie, mostly adenocarcinoma).